Welcome to our dedicated page for Skye Bioscience news (Ticker: SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.
Skye Bioscience (SKYE) is a clinical-stage biopharmaceutical innovator developing targeted therapies through cannabinoid receptor modulation. This page serves as the definitive source for verified company announcements, research milestones, and financial updates.
Investors and researchers will find timely updates on clinical trials, regulatory developments, and strategic partnerships. Our curated collection includes earnings reports, pipeline progress for nimacimab (peripheral CB1 inhibitor), and scientific presentations - all organized for efficient due diligence.
Key focus areas include metabolic disorder therapeutics, antibody-based drug development, and clinical safety data. Content is rigorously verified to ensure compliance with financial disclosure standards while maintaining accessibility for both specialist and general audiences.
Bookmark this page for structured access to SKYE's evolving position in biopharmaceutical innovation, with particular emphasis on obesity treatment research and peripheral endocannabinoid system modulation.
Skye Bioscience (NASDAQ: SKYE), a clinical-stage biopharmaceutical company specializing in metabolic health therapeutics, has granted stock options to a new non-executive employee. The Board of Directors approved a non-qualified stock option award to purchase 100,000 shares of common stock on May 7, 2025, under the company's Amended and Restated 2024 Inducement Plan.
The stock options have an exercise price of $1.82 per share, matching Skye's closing price on Nasdaq Global Select Market. The options will vest over four years, with 25% vesting after one year and the remaining vesting monthly over 36 months, contingent on continued employment.
Skye Bioscience (NASDAQ: SKYE) presented a clinical pharmacokinetic and pharmacodynamic model at the European Congress on Obesity that demonstrates peripheral CB1 inhibition alone is sufficient for weight loss, while central (brain) inhibition is not required. The model analyzed data from various CB1 inhibitors including nimacimab, monlunabant, and rimonabant.
The study revealed that nimacimab showed the greatest peripheral restriction compared to small molecule-based inhibitors, with minimal brain penetration while maintaining sufficient peripheral inhibition. The Phase 2 dose of nimacimab achieves peripheral CB1 engagement at >7x the inhibition threshold while remaining >600x below this threshold in the brain, suggesting a potentially superior therapeutic index with fewer neuropsychiatric side effects.
Skye Bioscience (NASDAQ: SKYE), a clinical-stage biotech company specializing in obesity and metabolic health disorders treatments, has scheduled its Q1 2025 earnings conference call for May 8th, 2025, at 1:30 PM PT/4:30 PM ET. The company will release its financial results after market close on the same day. Investors can access the live webcast, earnings release, financial tables, and presentation through Skye's Investor Relations website. A replay and transcript will be available post-call on the same platform.
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biotech company specializing in obesity and metabolic health disorders, has announced its participation in multiple high-profile conferences this May.
The company will engage in two key investment conferences:
- Citizens Life Sciences Conference in New York (May 8) - Featuring a presentation at 11:00 am ET and one-on-one meetings
- Craig-Hallum Institutional Investor Conference in Minneapolis (May 28) - Offering one-on-one meeting opportunities
Additionally, Skye will present a scientific poster at the European Congress on Obesity in Malaga, Spain on May 13. Interested parties can access available webcasts through the company's website.
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biopharmaceutical company specializing in metabolic health therapeutics, has announced a new stock option grant under its Amended and Restated 2024 Inducement Equity Incentive Plan. The Board of Directors approved on April 23, 2025, a non-qualified stock option award for 19,000 shares to one new non-executive employee.
The stock options, granted at an exercise price of $1.73 per share (matching Nasdaq Global Select Market closing price), will vest over four years. The vesting schedule includes 25% after one year, followed by 36 monthly installments, contingent on continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) for inducement awards to new employees.
Skye Bioscience (NASDAQ: SKYE) has announced promising preclinical results for its CB1 antibody, nimacimab, in treating obesity. In a diet-induced obesity model, the combination of nimacimab with tirzepatide achieved over 30% weight loss after 25 days of treatment. Nimacimab alone demonstrated 23.5% weight loss, comparable to monlunabant and tirzepatide monotherapies.
New in vitro data revealed nimacimab's superior potency characteristics through its non-competitive allosteric binding to CB1, showing stable effectiveness even under high agonist concentrations, unlike monlunabant. This differentiated mechanism suggests potential advantages in treating obesity without the neuropsychiatric side effects associated with small molecule CB1 inhibitors.
The company expects to release top-line randomized data from the Phase 2a CBeyond™ study in late Q3/early Q4 2025.
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biopharmaceutical company specializing in obesity and metabolic health disorders treatments, has announced that its executive team will be participating in the Piper Sandler Spring Biopharma Symposium. The event is scheduled for April 17th, 2025, in Boston, MA, where the company will be available for one-on-one meetings.
Skye Bioscience (NASDAQ: SKYE) has completed enrollment in its Phase 2a CBeyond™ trial of CB1 inhibitor nimacimab for obesity treatment, with 136 patients exceeding the initial target of 120. The company expects full top-line data in late Q3/early Q4 2025, ahead of schedule, and has extended the trial dosing to 52 weeks for enhanced long-term data.
Key financial highlights include a strong cash position of $68.4 million as of December 31, 2024, with runway projected through Q1 2027. The company reported a net loss of $26.6 million for 2024, significantly improved from $37.6 million in 2023. R&D expenses increased to $18.7 million in 2024 from $5.8 million in 2023, while G&A expenses rose to $17.7 million from $7.9 million.
The company raised approximately $83.6 million through two PIPE transactions in early 2024 and received a $2 million insurance settlement. Preclinical data from November 2024 showed significant dose-dependent weight loss and improved glucose tolerance, supporting nimacimab's potential in obesity treatment.
FAQ
What is the current stock price of Skye Bioscience (SKYE)?
What is the market cap of Skye Bioscience (SKYE)?
